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Researchers are calling for a
strengthening of the Antarctic
Treaty in the face of expected
growth in the search for
organisms on the continent that
may provide lucrative material for
biotechnology companies. The
call comes because of the
background of scientific
collaboration that has been in
place for more than 40 years
which has helped maintain an
almost unique international
collaboration to preserve the
continent and the species that
inhabit it.
But the environment of the polar
continent makes it especially
appealing for biotech companies.
Organisms that thrive in the frozen
soils and surrounding waters do
so because they have developed
unique biological coping
strategies. If researchers can
unravel the secrets of life in a cold
climate, the financial rewards
could be huge for businesses
involving chilling and freezing
technologies.
Bioprospectors are starting to
turn their attention to many of the
last frontiers, such as
hydrothermal vents, the deep
seabed, the water column of the
high seas and polar ice caps,
raising concerns about the unique
environment and status of
Antarctica. Scientists have already
discovered fish that survive
Antarctic waters by producing
their own ‘anti-freeze’. The
molecule responsible has been
patented and could be used
commercially to protect frozen
food, or keep ice cream soft in
freezers. Other organisms,
amongst the ‘extremophiles’
which flourish in harsh
environments, are believed to
have unique enzymes that could
revolutionise industrial processes.
There is also hope such novel
organisms may lead to the
discovery of othr chemicals such
as antibiotics. 
According to researchers at the
United Nations University in
Tokyo, interest from the biotech
companies in Antarctica’s
biological riches is growing.
Already, some 92 patents referring
to Antarctic organisms or
molecules extracted from them
have been filed in the US and a
further 62 patents have been filed
in Europe.
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A new report seeks to strengthen the cooperation between states with an
interest in Antarctica in the face of growing commercial interests in the
potential of polar organisms, writes Nigel Williams.
Cold shoulder: Researchers are keen to ensure that the protection afforded to all Antarctic wildlife over the past 40 years is main-
tained in the face of growing commercial pressures. Bioprospecting for organisms and their constituents is raising increasing alarm
for the future of one of the most unspoilt environments on Earth. (Photograph: Oxford Scientific Films.)
In 2002, Spain granted a patent
for the wound healing and skin,
hair and nail treatment properties
of a glycoprotein extracted from
Antarctic bacteria. In the same
year, an extract from an Antarctic
green algae was patented in
Germany for use in cosmetic skin
treatment.
The problem, according to a
report by Hamid Zakri and Sam
Johnston at the university’s
Institute of Advanced Studies, is
that although commercial
activities such as mining and
tourism are banned or regulated,
there is nothing to stop biotech
companies going into Antarctica
and searching or ‘bioprospecting’
for potentially lucrative organisms.
“If bioprospecting is done
properly, it can be useful and
beneficial for all and can have
minimum impact on the
environment, but you want it to be
controlled to prevent companies
from causing significant
environmental damage or
disrupting the scientific
operations down there,” Johnston
said.
Agreeing rules for companies
keen to work in Antarctica is
fraught with difficulties. Antarctica
has long been used by scientists
and international agreements
such as the Antarctic Treaty
ensure that scientific knowledge
is made freely available to all.
Commercial exploitation, and the
inevitable close guarding of
secrets, is against the spirit of the
treaty.
The treaty was signed in 1959
by the 12 countries active in
Antarctic research. These
comprised the US, Argentina,
Australia, Belgium, Chile, France,
Japan, New Zealand, Norway and
the UK. The countries signed up
to a pledge that Antarctica should
be used for peaceful purposes
only and that military personnel or
equipment should be used only
for scientific research or other
peaceful purpose.
The treaty also requires
countries to exchange information
regarding plans for scientific
programs in Antarctica to the
greatest possible extent and that
scientific personnel should be
exchanged between expeditions
and stations and that scientific
observations and results from
Antarctica should be exchanged
and made freely available.
While few scientists believe the
threat to Antarctica is imminent,
things could change drastically in
the next 10 years. 
Explorers first laid eyes on the
islands of the Antarctic peninsular
in 1819. They had speculated that
a southern continent existed and
given it a name — Terra incognita
Australis, the unknown southern
land. In 1820, the Russian explorer
Fabian Gottlieb von
Bellingshausen became the first
person to see the mainland. The
first camp was set up by a
Norwegian in 1899 and a flurry of
survey trips followed so that by
the 1940s, Antarctic exploration
was no longer the preserve of
privately funded entepreneurs as
governments established bases
on the continent.
The new report warns that so
far biological prospecting in
Antarctica has usually been
carried out be consortia made up
of public and private bodies,
principally universities, research
centres and biotechnology and
pharmaceutical companies. “This
has made it difficult to draw a
clear line between scientific and
commercial activities,” it says.
The Antarctic Treaty group’s
advisory body, the Scientific
Committee on Antarctic Research,
also raised concerns about
bioprospecting in a recent report.
It stated: “While no current
instance of harvesting for
biotechnology is known, there are
obvious environmental
ramifications of the taking of
animals and plants as a
commercial venture.” Their report
concludes that bioprospecting
should be watched closely as it
“may develop into important
pressures on Antarctic
resources.”
The new report highlights that
developing commercial products
from naturally occurring genetic
resources or biochemichal
processes is typically a long,
expensive and uncertain process,
Even so, annual sales derived
from traditional knowledge using
genetic resources are $3 billion for
the cosmetics and personal care
industry, $20 billion for the
botanical medicine sector and
$75 billion for the pharmaceutical
industry. More than 60 per cent of
the cancer drugs approved by the
US Food and Drug Administration
are of natural origin or are
modelled on natural products.
Another concern is that
companies with patents on
Antarctic organisms, or extracts
from them, may prevent scientists
from working on them freely.
Johnston says now is the time to
deal with the issue. Regulations to
control bioprospecting will have
to be agreed upon by the many
countries that control different
parts of Antarctica. But if biotech
companies start making
agreements with individual
governments, it will be much more
difficult to reach a global
agreement. “It’s going to be much
easier to put regulations in place
that are effective and meaningful
before there are vested interests,”
Johnston said. “It is imminent that
biotechnology companies will
take up bioprospecting
companies and will be significant
in the next 10 years. After that, the
horse may have bolted.”
David Walton, chief scientist at
the British Antarctic Survey said
the Antarctic treaty group had
recently discussed
bioprospecting. “As always, it’s
up to individual states to
determine what will be agreed.
Like all international activity it
takes a long time to get
everybody to understand what the
problem is and do something
about it,” he said.
Johnston said getting
regulations right in Antarctica now
would set a precedent for other
environments around the world
where flora and fauna could
attract biotech companies. “It’s a
way of showing how the world
should deal with bioprospecting
generally,” he said.
The report concludes that
although the physical impact of
bioprospecting is currently
addressed by the treaty,
establishing the legal and policy
basis that controls the
commercialisation of genetic
resources, in line with the basic
principles of the treaty as well as
equity and fairness, is a more
complex matter.
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